ZAVICEFTA® (CEFTAZIDIME AND AVIBACTAM)| Adult Dosing

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

Broad Coverage

Indications

Efficacy

Limited Treatment Options

Safety

Dosing

Adult Dosing

Paediatric Dosing

Adult Dosing

Consistent dosing across indications¹

Recommended dose for adult patients with estimated CrCl ≥51 mL/min (refer to SmPC for full dosing information)^*

Scroll left to view table

Type of Infection	Dose of ZAVICEFTA (ceftazidime-avibactam)	Frequency	Infusion time	Duration of treatment
cIAI^†‡	2 g/0.5 g	Every 8 hours	2 hours	5–14 days
cUTI, including pyelonephritis^‡	2 g/0.5 g	Every 8 hours	2 hours	5–10 days^§
HAP, including VAP^‡	2 g/0.5 g	Every 8 hours	2 hours	7–14 days
Bacteraemia associated with, or suspected to be associated with, cIAI, cUTI or HAP/VAP	2 g/0.5 g	Every 8 hours	2 hours	In accordance with the site of infection
Infections due to aerobic Gram-negative organisms in patients with limited treatment options^†‡	2 g/0.5 g	Every 8 hours	2 hours	Guided by severity of infection, the pathogen(s) and patient’s clinical and bacteriological progress^\|\|

No dose adjustment required in the elderly, patients with mild renal impairment (estimated CrCl ≥51 to ≤80 mL/min) and those with hepatic impairment.¹

The dose of ZAVICEFTA in adult patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated in adults using the Cockcroft–Gault formula.

To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.

There is very limited experience with the use of ZAVICEFTA for more than 14 days.

Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Abbreviations:

cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.

References:

ZAVICEFTA. Summary of Product Characteristics, 2022.

Dosing

Legal Category: S1A

Further information available upon request

PP-ZVA-IRL-0241. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

PP-UNP-IRL-0176. January 2023

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.